Objective To study the dynamics of CD8 + stem memory T cells (TSCM) and the impact of CD8 + TSCM cells on disease progression of human immunodeficiency virus-1 (HIV-1) infection.Methods Twenty-five cases with chronic HIV-1 infection receiving antiretroviral therapy (ART) with tenofovir plus efavirenz + lamivudine and 36 healthy controls were enrolled and observed.Peripheral blood mononuclear cells were stained with using CD3-APCCy7,CD4-FITC,CD8-PerCPCy5,CD45RA-PECy7,CCR7-APC,CD27-PE,CD95-Pacific Blue,CD38-PE,HLA DR-APC monoclonal antibodies,then CD8+ TSCM cell percentage were determined by flow cytometry.To compare the difference of CD8 + TSCM cell percentage between HIV-1 chronic infected persons and healthy subjects,and to analyze the relationship between CD8 + TSCM cell percentage and disease progression index (CD4 + T cell count,HIV-1 viral load and immune activation index).Results Chronic HIV-1 infection resulted in a decrease of the CD8 + TSCM cell proportion in HIV-1 patients.CD8 + TSCM cells positively correlated with CD4 +T cell counts and negatively correlated with plasma viral load and CD8 +T cell activation.Prolonged ART successfully recovered the CD8 + TSCM cells,and the dynamic change of CD8 + TSCM cells was in parallel with CD4 + T cell restoration and a decrease in the level of T cell immune activation.Conclusion In summary,this report identifies CD8 + TSCM as a correlate of protection from disease progression.HIV-1-specific CD8 + TSCM can presumably directly contribute to the design of T cell-based vaccines.%目的 观察人类免疫缺陷病毒-1(human immunodeficiency virus-1,HIV-1)慢性感染者外周血中CD8+干细胞样记忆型T细胞(CD8+ stem memory T cells,CD8+ TSCM)随治疗的动态变化,分析其与疾病进展的关系.方法 观察25例经抗反转录病毒治疗(antiretroviral therapy,ART)的慢性HIV-1感染者(治疗方案为替诺福韦+依非韦伦+拉米夫定)以及36例健康对照者,对样本外周血单个核细胞(peripheral blood mononuclear cells,PBMC)分别用CD3-APCCy7、CD4-FITC、CD8-PerCPCy5、CD45RA-PECy7、CCR7-APC、CD27-PE、CD95-Pacific Blue抗体和CD38-PE、HLA DR-APC抗体进行细胞表面染色并通过流式细胞仪检测CD8+ TSCM细胞比例.比较HIV-1慢性感染者和健康者CD8+ TSCM细胞比例的差异,并分析其与疾病进展指标(CD4+T细胞计数、HIV病毒载量以及免疫活化指标)的关系.结果 HIV-1慢性感染组的CD8+ TSCM细胞比例小于健康对照组;CD8+ TSCM细胞比例与CD4+T细胞计数呈正相关,与HIV-1病毒载量以及免疫活化指标CD38+ HLA-DR+ CD8+T细胞呈负相关;随着ART治疗,CD8+ TSCM细胞比例在144周后升至健康对照水平.结论 CD8+ TSCM在慢性HIV-1感染中发挥一定的保护作用,HIV-1相关特异性CD8+ TSCM细胞可能是未来T细胞疫苗设计的靶点.
展开▼
